Physician profile
Kenneth Robert Hoffman
NPI 1598976169
$15,206.85
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $776 · 2020: $4,592 · 2021: $2,845 · 2022: $2,643 · 2023: $4,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,500 · Consulting Fee: $1,388 · Travel and Lodging: $1,320 · Food and Beverage: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,500.00 |
| Consulting Fee | $1,387.50 |
| Travel and Lodging | $1,319.56 |
| Food and Beverage | $144.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,161.43 | 2019-2023 | |
| Incyte Corporation | $4,845.09 | 2020-2022 | |
| Pharmacosmos Therapeutics INC. | $2,963.59 | 2023 | Monoferric |
| Baxter Healthcare | $400.00 | 2019 | |
| Astrazeneca Uk Limited | $400.00 | 2020 | |
| Becton, Dickinson and Company | $250.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.03 | 2019 | |
| Agios Pharmaceuticals, INC. | $56.35 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.46 | 2020 | |
| Exelixis INC. | $29.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.